Literature DB >> 30768784

Association between primary language, a lack of mammographic screening, and later stage breast cancer presentation.

Katy E Balazy1, Cecil M Benitez1, Paulina M Gutkin1, Clare E Jacobson1, Rie von Eyben1, Kathleen C Horst1.   

Abstract

BACKGROUND: Health determinants are known to influence the stage of breast cancer presentation, but it is unclear to what extent language affects stage. This study investigates whether non-English-speaking (NES) patients present at a later stage than their English-speaking (ES) counterparts and whether language is associated with mammographic screening.
METHODS: This study was a retrospective, single-institution cohort analysis of women undergoing breast radiotherapy from 2012 to 2017 (n = 1057). Patients were categorized as ES (n = 904) or NES (n = 153). Ordinal logistic regression analysis identified variables associated with later stage presentation, including language, race/ethnicity, and age. A subcohort analysis investigated the influence of mammographic screening on stage for NES patients.
RESULTS: NES patients had greater odds of later stage disease than ES patients (odds ratio, 1.47; 95% confidence, 1.001-2.150). This association persisted across all races/ethnicities. An additional analysis examined age categories associated with mammographic screening. For women eligible for screening (ie, those 40-50 years old or older than 50 years), there was a significant association between language and stage. NES patients older than 50 years were twice as likely to present at an advanced stage in comparison with ES patients (16.19% vs 8.11%; P = .0082). An additional subset analysis accounted for mammograms. NES patients who did not undergo screening had a higher probability of stage III disease (40.3% of NES patients vs 12.7% of ES patients). There was no difference in stage between NES and ES patients who did undergo screening.
CONCLUSIONS: Language is independently associated with later stage breast cancer for NES patients, regardless of race/ethnicity. NES patients may have difficulty in accessing the health care system. Future interventions should seek to reduce language barriers for mammographic screening and diagnosis.
© 2019 American Cancer Society.

Entities:  

Keywords:  advanced stage; breast cancer; language; later stage presentation; mammographic screening; non-English-speaking patients; radiotherapy

Year:  2019        PMID: 30768784     DOI: 10.1002/cncr.32027

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Primary Spanish speakers and sun-protective behaviors: A cross-sectional study.

Authors:  Nicole M Vecin; Alberto J Caban-Martinez
Journal:  J Am Acad Dermatol       Date:  2022-03-26       Impact factor: 15.487

2.  Racial/ethnic differences in patient experiences with health care in association with earlier stage at breast cancer diagnosis: findings from the SEER-CAHPS data.

Authors:  Albert J Farias; Carol Y Ochoa; Gabriela Toledo; Soo-In Bang; Ann S Hamilton; Xianglin L Du
Journal:  Cancer Causes Control       Date:  2019-12-03       Impact factor: 2.506

3.  Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway.

Authors:  Xiong Wu; Shuanglong Chen; Chuanhui Lu
Journal:  Int J Mol Med       Date:  2019-11-13       Impact factor: 4.101

Review 4.  Factors promoting breast, cervical and colorectal cancer screenings participation: A systematic review.

Authors:  Federica Vallone; Daniela Lemmo; Maria Luisa Martino; Anna Rosa Donizzetti; Maria Francesca Freda; Francesco Palumbo; Elvira Lorenzo; Angelo D'Argenzio; Daniela Caso
Journal:  Psychooncology       Date:  2022-07-12       Impact factor: 3.955

Review 5.  A narrative review of sociodemographic risk and disparities in screening, diagnosis, treatment, and outcomes of the most common extrathoracic malignancies in the United States.

Authors:  Sarah Singh; Praveen Sridhar
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.